TR200100205T2 - Aterosklerotik lezyonların tedavisi için ACAT ve MMP inhibitörlerinin birlikte uygulanması. - Google Patents

Aterosklerotik lezyonların tedavisi için ACAT ve MMP inhibitörlerinin birlikte uygulanması.

Info

Publication number
TR200100205T2
TR200100205T2 TR2001/00205T TR200100205T TR200100205T2 TR 200100205 T2 TR200100205 T2 TR 200100205T2 TR 2001/00205 T TR2001/00205 T TR 2001/00205T TR 200100205 T TR200100205 T TR 200100205T TR 200100205 T2 TR200100205 T2 TR 200100205T2
Authority
TR
Turkey
Prior art keywords
acat
administration
mmp inhibitors
treatment
atherosclerotic lesions
Prior art date
Application number
TR2001/00205T
Other languages
English (en)
Inventor
Michael Andrew Bocan Thomas
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of TR200100205T2 publication Critical patent/TR200100205T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Bu bulus bir memelide aterosklerotik lezyonlarin histiosit ve düz kas hücresi bilesenini azaltmak, böylece var olan lezyonlarin genislemesini ve yeni lezyonlarin gelismesini önlemek için ve plak kopmasini engellemek ve lezyon gerilemesini tesvik etmek için ACAT ve MMP inhibitörlerinin birlikte uygulanmasina iliskindir.
TR2001/00205T 1998-07-21 1999-06-18 Aterosklerotik lezyonların tedavisi için ACAT ve MMP inhibitörlerinin birlikte uygulanması. TR200100205T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21

Publications (1)

Publication Number Publication Date
TR200100205T2 true TR200100205T2 (tr) 2001-05-21

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00205T TR200100205T2 (tr) 1998-07-21 1999-06-18 Aterosklerotik lezyonların tedavisi için ACAT ve MMP inhibitörlerinin birlikte uygulanması.

Country Status (25)

Country Link
EP (1) EP1098662A2 (tr)
JP (1) JP2002521328A (tr)
KR (1) KR20010083134A (tr)
CN (1) CN1310629A (tr)
AP (1) AP2001002035A0 (tr)
AU (1) AU4701799A (tr)
BG (1) BG105162A (tr)
BR (1) BR9912296A (tr)
CA (1) CA2335062A1 (tr)
CZ (1) CZ2001126A3 (tr)
EA (1) EA200100153A1 (tr)
EE (1) EE200100046A (tr)
HR (1) HRP20010055A2 (tr)
HU (1) HUP0102880A3 (tr)
ID (1) ID30030A (tr)
IL (1) IL140982A0 (tr)
IS (1) IS5809A (tr)
NO (1) NO20010291L (tr)
OA (1) OA11584A (tr)
PL (1) PL346011A1 (tr)
SK (1) SK502001A3 (tr)
TR (1) TR200100205T2 (tr)
WO (1) WO2000004892A2 (tr)
YU (1) YU3501A (tr)
ZA (1) ZA200100294B (tr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1210401A (en) * 1999-11-05 2001-06-06 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
JP2003534239A (ja) * 1999-12-17 2003-11-18 ヴァージコア・インコーポレーテッド 新規なスクシナート化合物、組成物、並びに使用及び調製方法
WO2002020009A1 (fr) * 2000-09-01 2002-03-14 Sankyo Company, Limited Compositions medicales
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
WO2003082288A1 (en) * 2002-04-03 2003-10-09 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
JP4617449B2 (ja) * 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するｎ−ヒドロキシアミド誘導体
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
GEP20012511B (en) * 1995-08-04 2001-08-27 Warner Lambert Co Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
EA001561B1 (ru) * 1996-05-17 2001-04-23 Варнер-Ламберт Компани Бифенилсульфонамидные ингибиторы матричных металлопротеиназ
NZ333063A (en) * 1996-09-04 2000-12-22 Warner Lambert Co Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
ID30030A (id) 2001-11-01
AU4701799A (en) 2000-02-14
IS5809A (is) 2001-01-12
HUP0102880A3 (en) 2002-11-28
CZ2001126A3 (cs) 2002-01-16
NO20010291D0 (no) 2001-01-18
HRP20010055A2 (en) 2002-04-30
WO2000004892A2 (en) 2000-02-03
CN1310629A (zh) 2001-08-29
YU3501A (sh) 2005-06-10
PL346011A1 (en) 2002-01-14
ZA200100294B (en) 2002-01-10
AP2001002035A0 (en) 2001-03-31
NO20010291L (no) 2001-01-18
KR20010083134A (ko) 2001-08-31
CA2335062A1 (en) 2000-02-03
OA11584A (en) 2004-07-20
EP1098662A2 (en) 2001-05-16
EA200100153A1 (ru) 2001-08-27
BG105162A (en) 2001-12-29
HUP0102880A2 (en) 2002-06-29
EE200100046A (et) 2002-06-17
SK502001A3 (en) 2002-06-04
BR9912296A (pt) 2001-04-17
IL140982A0 (en) 2002-02-10
JP2002521328A (ja) 2002-07-16
WO2000004892A3 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
TR200100205T2 (tr) Aterosklerotik lezyonların tedavisi için ACAT ve MMP inhibitörlerinin birlikte uygulanması.
TR200100605T2 (tr) Arilpiperazinler ve bunların metaloproteinaz inhibe edici maddeler (MMP) olarak kullanımı
TR199800815A2 (tr) Sülfonilaminokarbonasitler.
TR200003808T2 (tr) Bir cox-2 inhibitörü içeren farmasötik kombinasyon
AU2713600A (en) Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
NO20003565L (no) Sulfonylaminoderivater som hemmer matriks-nedbrytende metalloproteinaser
DE69738186D1 (de) Erweiterungsstation für einen tragbaren Computer, der eine zusätzliche Batterie enthält
TR200100149T2 (tr) Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler
AR027814A1 (es) Inhibidores del factor viia
TR199903287T2 (tr) Matriks metaloproteinazlarinin ters hidroksamat inhibitörleri.
NO993587L (no) Sulfonamid-metalloprotease-inhibitorer
DE69941723D1 (de) Kombinierte standby-instrumente für flugzeug
TR200100672T2 (tr) Yeni izoksazolinon antibakteriyel ajanları
NO995267D0 (no) Leptin som en inhibitor av tumorcelleprofilering
DE69907222D1 (de) Energieverbrauchsmessen
TR199900762T2 (tr) Stresle aktiflestirilen protein kinazlarinin engellenme yöntemi.
FI980716A0 (fi) Arrangemang i samband med en hydraulvaetskedriven slaganordning, saosom t.ex. i en krossanordning
DK1131356T3 (da) Monoklonalt alfa-D (ITGAD)-antistof til anvendelse i behandlingen af CNS-læsioner foranlediget af trauma
DE69838209D1 (de) Nichtgesinterte Positivelektrode für alkalische Speicherbatterie und diese verwendende alkalische Speicherbatterie
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
TR200100133T2 (tr) FKBP İnhibitörleri
TR200000624T2 (tr) Bir enzimin etkinliğinin arttırılması ile ilgili bir yöntem.
TR199800847A3 (tr) Bir anjiyotensin dönüstürücü enzim inhibitörünün sabit doz bilesimi.
DE59911513D1 (de) Prüfanordnung für Bondpad
TR200100013T2 (tr) N-tert-butilhidroksilaminin yeni tuzları.